Modern management of relapsed and refractory aggressive B-cell lymphoma: A perspective on the current treatment landscape and patient selection for CAR T-cell therapy

Lymphoma

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

healthbook TIMS Oncology Hematology

Ring A, Müller A

doi: 10.36000/hbT.OH.2019.01.005

Lymphoma

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

N Engl J Med.

Abramson JS, McGree B, Noyes S, Plummer, S, Wong C, Chen Y, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC

doi: 10.1056/NEJMc1704610.

Central Nervous System Tumors

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

N Engl J Med.

Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B

doi: 10.1056/NEJMoa1610497

Lymphoma

Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.

J Med Case Rep.

Jurczak W, Bryk AH, Mensah P, Gałązka K, Trofimiuk-Müldner M, Wyrobek Ł, Sawiec A, Skotnicki AB

doi: 10.1186/s13256-016-0875-x.

Leukemia

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

J Clin Oncol.

Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, Wood B, Lozanski A, Byrd JC, Heimfeld S, Riddell SR, Maloney DG

doi: 10.1200/JCO.2017.72.8519.

Lymphoma

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

Lancet Oncol.

Chiappella A, Martelli M, Angelucci E, Brusamolino E, Evangelista A, Carella AM, Stelitano C, Rossi G, Balzarotti M, Merli F, Gaidano G, Pavone V, Rigacci L, Zaja F, D'Arco A, Cascavilla N, Russo E, Castellino A, Gotti M, Congiu AG, Cabras MG, Tucci A, Agostinelli C, Ciccone G, Pileri SA, Vitolo U

doi: 10.1016/S1470-

Central Nervous System Tumors

CD70, a novel target of CAR-T-cell therapy for gliomas

Neuro Oncol.

Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J

doi: 10.1093/neuonc/nox116.

Lymphoma

Primary Cutaneous Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma

Am J Dermatopathol.

Kempf W, Torricelli R, Zettl A, Zimmermann AK, Berisha A, Ghielmini M

doi: 10.1097/DAD.

Lymphoma

A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development

BMC Nephrol.

Khandelwal A, Trinkaus MA, Ghaffar H, Jothy S, Goldstein MB

doi: 10.1186/s12882-016-0349-9.

Related content

CD19-Directed CAR T Cells Treatment in a Patient With Refractory DLBCL and CNS Involvement

Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma

Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy

Single-agent MOR208 salvage and maintenance therapy in a patient with refractory/relapsing diffuse large B-cell lymphoma: a case report.

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib

Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study

CD70, a novel target of CAR-T-cell therapy for gliomas

Primary Cutaneous Anaplastic Lymphoma Kinase-Positive Large B-Cell Lymphoma

A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development